Share
Anti-Fungal Treatment Market Size, Share, and Analysis, By Drug Type (Echinocandins, Azoles, Polyenes, and Allylamines), By Route of Administration (Oral, Topical, and Parenteral), By Indication (Dermatophytosis, Aspergillosis, Candidiasis, and Others), By Distribution Channel (Hospital Pharmacies, Retails Pharmacies & Drug Stores, and Others), and By Region (North America, Europe, Asia-Pacific, And Rest of the World) And Regional Forecast 2023-2032
Anti-Fungal Treatment Market is expected to grow at a CAGR of 3.3% in the forecast period (2023-2032), with the market size valued at USD 12.27 billion in 2021 and projected to reach USD 17.4 billion by 2032.
Fungi are microorganisms that can survive in a variety of conditions and cause different type of illnesses in people, ranging from skin infections to systemic infections by inhalation. These illnesses are frequently caused by exposure to unsanitary conditions or by impaired immune systems. As a result, people may have fungal infections on their skin, hair, and lungs, fueling market expansion. This proliferation is being aided by common fungal infections such as ringworm, athlete's foot, and fungal nail infections. Antifungal medications are critical in avoiding fungal growth and infection especially over-the-counter choices for skin infections, is favorably boosting the growth of the antifungal drug industry.
Anti-Fungal Treatment Market is expected to reach USD 17.4 billion, growing at a CAGR of 3.3% owing to the global rise in the occurrence of fungal infections that has driven producers to create enhanced formulation drugs for better clinical outcomes. This, in turn, is fuelling market expansion throughout the predicted period. As a result, producers are focused on new drug formulations that can be manufactured utilizing nanotechnology.
Source: Fatpos Global
Based on the Drug Type, the market is divided into Echinocandins, Azoles, Polyenes, and Allylamines. In 2022, Azoles sector led the market, and it is predicted to dominate throughout the projection period. The market for azoles, which include systemic antifungal medications like fluconazole and ketoconazole that are highly recommended for treating fungal infections, is expected to expand. Due to their affordability and effectiveness in treating invasive systemic fungal infections, echinocandins, notably micafungin and caspofungin, derived from natural fungal sources, are anticipated to have the highest CAGR during forecasted period.
By Route of Administration, the Anti-Fungal Treatment Market is segmented into Oral, Topical, and Parenteral. Topical segment sector led the market, and it is predicted to dominate throughout the projection period. Due to a rise in the use of topical medications around the world, the topical antifungal mode of administration has the biggest market share for antifungal medications. Additionally, the market is benefiting from the expanding use of topical medications by doctors to treat dermatological fungal infections.
Source: Fatpos Global
Increase in Nosocomial Infections to Boost the Market for Antifungal Drugs
Fungal infections have become a major public health concern around the world in recent years. Furthermore, the prevalence of nosocomial infections is fueling market expansion. The increasing occurrences of cancer, an increase in hematopoietic stem cell transplantation, and other factors that result in immune system weakness are to blame for the rise in nosocomial infections. Aspergillosis, for example, is typically found in patients who are immunocompromised to varying degrees. According to the World Health Organization (WHO), roughly 30% of patients in intensive care units in high-income countries have at least one healthcare-associated infection. In contrast, the frequency of intensive care-acquired infection is 2-3 times higher in middle to low-income nations than in high-income ones. The rising frequency of hospital-acquired infections is predicted to supplement and drive the market's expansion.
Increased R&D efforts are Expected to Boost the Market Growth
Increasing prevalence of fungal diseases and the difficulties in treating them increased investment in research and development (R&D) operations, which result in the creation of new antifungal medications. Currently, commonly used antifungal medicines have limits, particularly in treating invasive infections, necessitating the development of novel formulations. The high morbidity and mortality rates linked with yeast infections highlight the need for better treatments. Resistance to existing aspergillosis treatments, as well as recurring toxicity problems, are driving R&D and clinical trials for innovative antifungal medications. Major pharmaceutical corporations are actively involved in a variety of R&D projects in this field.
High Adverse Effects and the Use of Conventional Drugs is Hurting the Market
Growing availability of expensive and generic medications for the routine treatment of a fungal infection is limiting market expansion. Additionally, the market's expansion is being hampered by the substantial side effects of the antifungal medications used to treat fungal infections. Amphotericin B, for instance, which is widely recommended for fungal infections, has several negative side effects. Furthermore, during the projected period, the market would be hampered by strict government regulations, patent expirations, an increase in fungal resistance, and fake medications.
Anti-Fungal Treatment Market is segmented based on regional analysis into five major regions: North America, Latin America, Europe, Asia Pacific and the Middle East and Africa. North America is predicted to lead the global market, owing to increased hygiene awareness, an increase in the frequency of fungal diseases, and the use of sophisticated therapies. Because of improved healthcare infrastructure, greater healthcare spending, and an increasing number of patients with fungal infections, Europe is expected to hold the second-largest market share.
Source: Fatpos Global
The COVID-19 outbreak had resulted in the economic downfall. Several countries had imposed lockdowns and applied travel restrictions to control the spread of the virus. Due to the outbreak, which caused disruptions in the healthcare industry and supply chains worldwide, the market for antifungal medications initially encountered limits. Flight restrictions and strong anti-pandemic measures impacted the first quarter of 2020. However, once economies reopened, the market began to rebound in the second quarter. Government-imposed national lockdowns to contain COVID-19 affected supply networks and impacted demand for antifungal medications as health facilities struggled to sustain their supply chains.
|
ATTRIBUTE |
DETAILS |
|
Study Period |
2018-2032 |
|
Base Year |
2022 |
|
Forecast Period |
2022-2032 |
|
Historical Period |
2019-2021 |
|
Growth Rate |
CAGR of 3.3% from 2022-2032 |
|
Unit |
Value (USD Billion) |
|
Segmentation |
Main Segments List |
|
By Drug Type |
|
|
By Route of Administration |
|
|
By Indication |
|
|
By Distribution Channel |
|
|
By Region |
|
Anti-Fungal Treatment Market size was values at USD 12.27 billion in 2021 and is projected to reach the value of USD 17.4 billion in 2032, exhibiting a CAGR of 3.3% during the forecast period.
The Anti-Fungal Treatment Market is the healthcare industry focused on discovering and delivering drugs and cures for fungal infections in people and animals. This market encompasses a variety of antifungal medications and diagnostic technologies that are addressing the rising occurrence of fungal infections, particularly among immunocompromised people, and expanding treatment choices.
The Azole segment and the Topical segment accounted for the largest Anti-Fungal Treatment Market share.
Key players in the Anti-Fungal Treatment Market include Pfizer Inc., Novartis AG, Gilead Sciences, Inc., Merck & Co., Inc., Johnson & Johnson, Astellas Pharma Inc., GlaxoSmithKline plc., AbbVie Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Sanofi S.A., Bayer AG, Teva Pharmaceutical Industries Ltd., Mylan N.V., Basilea Pharmaceutica AG, and other prominent players.
Increase in Nosocomial Infections and rising R&D efforts are the factors driving the Anti-Fungal Treatment Market.
Select License Type
Select License Type
FATPOS CLIENT Appriciation DURING THE PROJECT
Working with Fatpos Global, allowed us to take advantage of their knowledge and easy approach, allowing us to collect important data utilizing a variety of techniques. The results were clearly presented and explained, and FG responded to our questions with speed and expertise.
|
Swiss-based global building materials manufacturer |
The analyses and presentations Fatpos Global have produced for us have been of a very high caliber and have allowed us to proactively improve our customer relationship management. They have also done so while maintaining complete anonymity. Without any doubt, we suggest Fatpos Global to you.
|
|
Tech-powered construction company |
We appreciate the team’s punctuality, flexibility in terms of report modification, post report purchase support and pleasant reaction all around. Overall, my experience with this company was nothing but positive, and I couldn't be more grateful for their excellent service. Thank you for all that you do!
|
|
American global management consulting firm |
We are able to concentrate on the topics and implications that are most important to our clients thanks to the adaptability and responsiveness of the team at Fatpos Global. We would highly recommend this company to anyone in need of their services, and I will certainly be using them again in the future.
|
|
Headquartered in Zug, Switzerland, leading supplier of medical and surgical instrument |
To better study our client demographics, develop the ideal product-price architecture, and enhance our target marketing initiatives, we hired Fatpos Global. Every component of the project was completed, and we are very happy with the useful insights and actionable results.
|
|
Kosovan company, A leading organic fertilizers producer |
Thank you for your team's generous assistance, The final report was delivered to me, and I find it to be really helpful. Also, you may be sure that I will get in touch with you if I ever require fresh materials for market research. Gratitude once more.
|
|
German specialty chemicals company based in Cologne, Germany |
